Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARRY-614, p38/Tie2 inhibitor · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ARRY-614 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARRY-614, p38/Tie2 inhibitor; oral | DRUG | Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule |
Key Inclusion Criteria (Part 1 and Part 2): * Diagnosis of MDS by bone marrow biopsy. * International Prognostic Scoring System (IPSS) score of low or intermediate-1 risk MDS. * May have received prior therapy for MDS. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2...
Top 20 of 34 competitors
ARRY-614 is an investigational small molecule being studied for the treatment of Myelodysplastic Syndromes (MDS), specifically in patients with low or intermediate-1 risk disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
ARRY-614 is a p38/Tie2 inhibitor, meaning it targets the p38 mitogen-activated protein kinase and the Tie2 receptor tyrosine kinase. By inhibiting these targets, the drug is designed to modulate signaling pathways involved in the development and progression of Myelodysplastic Syndromes.
ARRY-614 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical trials for the treatment of Myelodysplastic Syndromes.
ARRY-614 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied in patients with low or intermediate-1 risk Myelodysplastic Syndromes.
ARRY-614 has been studied in two completed Phase 1 clinical trials: NCT00916227, which enrolled 45 patients, and NCT01496495, which enrolled 71 patients. Both trials were conducted in the United States and involved patients with low or intermediate-1 risk Myelodysplastic Syndromes.
ARRY-614 is the drug name, and p38/Tie2 inhibitor describes its mechanism of action. The drug is a small molecule that inhibits both p38 and Tie2, and it is being developed by Pfizer for the treatment of Myelodysplastic Syndromes.